Sphingosine and sphingolipids accumulate in NPC1 and have been proposed to contribute to NPC pathology [58,59,60], and miglustat, a glycosphingolipid synthesis inhibitor, has shown efficacy in slowing NPC1 disease progression [61,62]. This evidence concerns the gene NPC1 and nasopharyngeal carcinoma.